Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Equity Capital Markets

Sejong Medical Co Ltd / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/27002" target="_blank" data-smartkarma-citation="entities:27002:1">Sejong Medical Co Ltd (258830 KS)</a> is an IPO in Korea that is expected to be completed in May 2018. Sejong Medical is a medical device maker in Korea. The IPO deal size is expected to be between US$21 million to US$26 million. Korea Investment &amp; Securities is the lead banker on this deal. The Korean IPO market has been highly successful YTD. IPOs this year such as <a href="https://www.smartkarma.com/entities/26754" target="_blank" data-smartkarma-citation="entities:26754:1">Carelabs Co Ltd (263700 KS)</a>, <a href="https://www.smartkarma.com/entities/25912" target="_blank" data-smartkarma-citation="entities:25912:1">Cafe24 Corp (042000 KS)</a>, and <a href="https://www.smartkarma.com/entities/26763" target="_blank" data-smartkarma-citation="entities:26763:1">JTC Inc/Fukuoka (950170 KS)</a> all are up more than 100% than their IPO prices…

Sejong Medical Co Ltd (258830 KS) is an IPO in Korea that is expected to be completed in May 2018. Sejong Medical is a medical device maker in Korea. The IPO deal size is expected to be between US$21 million to US$26 million. Korea Investment &amp; Securities is the lead banker on this deal. The Korean IPO market has been highly successful YTD. IPOs this year such as Carelabs Co Ltd (263700 KS), Cafe24 Corp (042000 KS), and JTC Inc/Fukuoka (950170 KS) all are up more than 100% than their IPO prices…

Korea / Special Sits, Pairs, Index Rebalancing, Clepsydra Capital

Sanghyun Park

Korea / Special Sits, Pairs, Index Rebalancing

Thematic (Sector/Industry)

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

South Korea

Sewoonmedical Co., Ltd. mamanufactures medical products such as electric surgical operation equipment and medical drug injectors. Main products are wound drainage system, catheters and tubes that are used in hospital.  The company also merchandises some medical products and exports its products to overseas.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sewoonmedical (100700 KS)

Sejong Medical IPO Preview (Part 1)

Sejong Medical Co Ltd (258830 KS) is an IPO in Korea that is expected to be completed in May 2018. Sejong Medical is a medical device maker in...

Douglas Kim

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...

Sanghyun Park

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)